PLX — Protalix Biotherapeutics Balance Sheet
0.000.00%
- $148.30m
 - $114.90m
 - $53.40m
 
- 55
 - 56
 - 39
 - 49
 
Annual balance sheet for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 38.5 | 39 | 22.2 | 44.6 | 34.8 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2 | 3.44 | 4.59 | 5.27 | 2.91 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 55.7 | 61.7 | 44.9 | 69.9 | 60.1 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 10.4 | 9.92 | 9.64 | 10.9 | 10 | 
| Other Long Term Assets | |||||
| Total Assets | 67.9 | 73.7 | 55.8 | 84.4 | 73.4 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 86.5 | 33.2 | 32.4 | 45.5 | 25.6 | 
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 95 | 79.7 | 66.4 | 50.9 | 30.2 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -27 | -6.04 | -10.6 | 33.6 | 43.2 | 
| Total Liabilities & Shareholders' Equity | 67.9 | 73.7 | 55.8 | 84.4 | 73.4 | 
| Total Common Shares Outstanding |